Verastem, Inc. (2VSA.F)

EUR 4.28

(-35.15%)

Revenue Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual revenue in 2022 was 2.59 Million USD , up 26.45% from previous year.
  • Verastem, Inc.'s latest quarterly revenue in 2024 Q2 was 10 Million USD , down 0.0% from previous quarter.
  • Verastem, Inc. reported a annual revenue of 2.05 Million USD in annual revenue 2021, down -97.68% from previous year.
  • Verastem, Inc. reported a annual revenue of 88.51 Million USD in annual revenue 2020, up 407.08% from previous year.
  • Verastem, Inc. reported a quarterly revenue of - USD for 2024 Q1, down 0.0% from previous quarter.
  • Verastem, Inc. reported a quarterly revenue of - USD for 2023 Q3, down 0.0% from previous quarter.

Annual Revenue Chart of Verastem, Inc. (2022 - 2011)

Historical Annual Revenue of Verastem, Inc. (2022 - 2011)

Year Revenue Revenue Growth
2022 2.59 Million USD 26.45%
2021 2.05 Million USD -97.68%
2020 88.51 Million USD 407.08%
2019 17.45 Million USD -34.67%
2018 26.71 Million USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Revenue Comparison of Verastem, Inc.

Name Revenue Revenue Difference
BioNTech SE 3.81 Billion EUR 99.932%
CureVac N.V. 53.75 Million EUR 95.171%
Biotest Aktiengesellschaft 684.6 Million EUR 99.621%
Biotest Aktiengesellschaft 684.6 Million EUR 99.621%
BRAIN Biotech AG 55.33 Million EUR 95.309%
Formycon AG 77.69 Million EUR 96.659%
Heidelberg Pharma AG 9.85 Million EUR 73.668%
Medigene AG 6.03 Million EUR 56.977%